GLAXF:OTO-GlaxoSmithKline Plc (USD)

COMMON STOCK | Drug Manufacturers—General | OTC Pink

Last Closing

USD 17.94

Change

-1.26 (-6.56)%

Market Cap

USD 97.89B

Volume

500.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Drug Manufacturers—General

ETFs Containing GLAXF

DX2K:F Xtrackers - FTSE 100 Shor.. 0.00 % 0.00 %

N/A

USD 0.02B
DX2K:XETRA Xtrackers FTSE 100 Short .. 0.00 % 0.00 %

N/A

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers—General) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.08% 29% F 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.08% 29% F 50% F
Trailing 12 Months  
Capital Gain -12.49% 34% F 66% D+
Dividend Return 3.04% 62% D 57% F
Total Return -9.44% 31% F 67% D+
Trailing 5 Years  
Capital Gain -24.46% 28% F 55% F
Dividend Return 15.17% 90% A- 69% C-
Total Return -9.29% 38% F 57% F
Average Annual (5 Year Horizon)  
Capital Gain 0.27% 36% F 38% F
Dividend Return 3.97% 50% F 42% F
Total Return 3.70% 91% A- 75% C
Risk Return Profile  
Volatility (Standard Deviation) 8.78% 94% A 96% N/A
Risk Adjusted Return 45.23% 64% D 65% D
Market Capitalization 97.89B 83% B 100% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector